All In Biotech

Drug Trial Radar · NCT02422719

Radotinib as 3rd or Later Line Therapy in CP-CML

Radotinib Efficacy and Safety Validation in Chronic Phase Chronic Myeloid Leukemia Patients Who Are Intolerant or Resistant to at Least Two Tyrosine Kinase Inhibitors As a Third or Subsequent Line Therapy

Last checked: Nov 19, 2026Latest source record: May 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

73

Planned (sponsor's estimate)

Start

Apr 2015

Primary completion

Mar 2019

Study completion Mar 2019

Sponsor

Lead sponsor
Ulsan University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 21, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether radotinib is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors.

Conditions

  • Chronic Myeloid Leukemia

Interventions

  • RadotinibDrug

    Radotinib 400mg bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Major cytogenetic responseTime frame: by 12 months after radotinib treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ulsan University Hospital

    Ulsan, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.